November 20, 2018
A decade ago, patients with newly diagnosed multiple myeloma typically survived 3 to 5 years. However, the development of highly effective therapies — including proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies — has greatly improved outcomes. In addition to extending survival, these newer agents are associated with considerably less toxicity. “We not only have this...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand